Seekyo is a French biotechnology company focused on developing innovative treatments for solid tumours by targeting the tumour microenvironment (TME). Their proprietary approach, termed Tumor Activated Therapy™, aims to induce tumour self-destruction by exploiting specific proteins produced within the TME.

The company's lead compound, SKY01, has demonstrated promising results in preclinical studies, showing efficacy and safety in both small and large animal models. This novel therapy targets functional proteins in the TME, allowing for tumour recognition and selective drug activation, which may overcome challenges associated with tumour heterogeneity.

Seekyo's mission is to provide patients with safe and effective treatments that improve quality of life. They are advancing their internal programs, SKY01 and SKY02, towards human clinical trials and are open to partnerships with pharmaceutical companies, biotechs, and academic institutions to further develop and optimize their innovative technology.